Acebrophylline 200 mg + Montelukast 10 mg Tablet Franchise in Mumbai Maharashtra

Respiratory PCD Pharma Opportunities in Delhi NCR

Acebrophylline + Montelukast Tablet Supplier in Chennai Tamil Nadu

Bronchodilator & Leukotriene Inhibitor PCD Franchise in Kolkata West Bengal

Asthma and COPD Combination Therapy Distribution in Bangalore Karnataka
Acebrophylline Montelukast Tablet Export & Manufacturing in Hyderabad Telangana

Home/Products /acebrophylline-200-mg-montelukast-10-mg-tablet

Abrostep M Tablet

Composition : Acebrophylline (200mg) + Montelukast (10mg)

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Abrostep M Tablet is a powerful respiratory formulation containing Acebrophylline (200 mg) and Montelukast (10 mg). This combination delivers a synergistic bronchodilator and anti-inflammatory effect, providing effective relief in asthma, bronchitis, and chronic obstructive pulmonary disease (COPD).

Acebrophylline, a xanthine derivative with mucolytic and bronchodilating properties, improves airway clearance, enhances oxygen flow, and reduces mucus viscosity. Montelukast, a selective leukotriene receptor antagonist, prevents airway inflammation and allergic bronchoconstriction, improving overall lung function and respiratory comfort.

This dual-action therapy ensures both symptomatic relief and long-term control, helping patients breathe easier while reducing dependency on acute inhaler use. It is widely prescribed by pulmonologists and general physicians for managing chronic airway disorders.

Belonging to the respiratory & pulmonology segment, Abrostep M Tablet is a high-potential B2B product for PCD pharma franchise, third-party manufacturing, and export channels. Its high clinical efficacy and recurring demand in both institutional and retail markets make it a profitable choice for pharma distributors across India.

Read More

About the Product

Abrostep M Tablet is a powerful respiratory formulation containing Acebrophylline (200 mg) and Montelukast (10 mg). This combination delivers a synergistic bronchodilator and anti-inflammatory effect, providing effective relief in asthma, bronchitis, and chronic obstructive pulmonary disease (COPD).

Acebrophylline, a xanthine derivative with mucolytic and bronchodilating properties, improves airway clearance, enhances oxygen flow, and reduces mucus viscosity. Montelukast, a selective leukotriene receptor antagonist, prevents airway inflammation and allergic bronchoconstriction, improving overall lung function and respiratory comfort.

This dual-action therapy ensures both symptomatic relief and long-term control, helping patients breathe easier while reducing dependency on acute inhaler use. It is widely prescribed by pulmonologists and general physicians for managing chronic airway disorders.

Belonging to the respiratory & pulmonology segment, Abrostep M Tablet is a high-potential B2B product for PCD pharma franchise, third-party manufacturing, and export channels. Its high clinical efficacy and recurring demand in both institutional and retail markets make it a profitable choice for pharma distributors across India.

Common side effects may include nausea, headache, abdominal discomfort, drowsiness, or mild dizziness. Rarely, allergic skin reactions, mood changes, or palpitations may occur. Contact your doctor immediately if you experience severe breathing difficulty or persistent side effects.

Abrostep M Tablet is indicated for the treatment of asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and allergic airway disorders. It helps in reducing wheezing, coughing, shortness of breath, and other symptoms associated with respiratory obstruction.

Take Abrostep M Tablet exactly as prescribed by your physician, preferably after meals. Do not stop the medication suddenly without consulting your doctor. Avoid alcohol and smoking during the treatment. Inform your healthcare provider if you have liver, kidney, or heart conditions.

Store Abrostep M Tablet in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep it tightly closed and out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation